Anticoagulation: Updated Guidelines for Outpatient Management.

Area of Science:

• Cardiology
• Hematology
• Pharmacology

Background:

• Anticoagulation therapy is vital for preventing and treating venous thromboembolism (VTE) and stroke in atrial fibrillation (AF).
• Direct oral anticoagulants (DOACs) are first-line for VTE and nonvalvular AF, while vitamin K antagonists (VKAs) are preferred for mechanical valves and valvular AF.

Purpose of the Study:

• To review current recommendations and emerging evidence for anticoagulation therapies.
• To highlight the mechanisms of action, clinical applications, and reversal strategies for anticoagulants.

Main Methods:

• Literature review of anticoagulation guidelines and clinical studies.
• Comparison of VKA and DOAC mechanisms, efficacy, and safety profiles.
• Discussion of bleeding risk assessment and management strategies.

Main Results:

• DOACs offer immediate anticoagulation, enabling outpatient VTE treatment for select low-risk patients.
• Low-molecular-weight heparin remains a first-line option for VTE with active cancer, though DOACs show promise.
• Validated bleeding risk assessments (e.g., HAS-BLED) are essential for monitoring and management.

Conclusions:

• DOACs and VKAs represent key therapeutic options for VTE and AF, each with distinct indications and properties.
• Effective reversal agents like idarucizumab and andexanet alfa are critical for managing DOAC-associated bleeding.
• Comprehensive risk assessment and management are paramount in anticoagulation therapy.